Min K. Tsai
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Min K. Tsai has a total of 100 co-authors. Here are the top co-authors by number of shared publications:
- Laura Andrejka
Department of Genetics, Stanford University School of Medicine, Stanford, California
76 shared publications - Christopher W. Murray
Cancer Biology Program, Stanford University School of Medicine, Stanford, California
50 shared publications - Dmitri A. Petrov
Department of Biology, Stanford University, Stanford, CA 94305, USA
50 shared publications - Hongchen Cai
Department of Genetics, Stanford University School of Medicine, Stanford, California
48 shared publications - Christian A. Kunder
Department of Pathology, Stanford University School of Medicine, Stanford, California
46 shared publications - Chuan Li
Department of Biology, Stanford University, Stanford, California
46 shared publications
Latest Publications
- Open Access
- 12 January 2026
- Published by American Association for Cancer Research (AACR)
Table S7 from EML4−ALK Variant-Specific Genetic Interactions Shape Lung Tumorigenesis
Supplementary Table 7 shows the prevalence of alterations in all genes assayed for the five most commonly occurring EML4-ALK variants in the NSCLC cohort (V3, V1, V2, V5' and V5).
- 12 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S7 from EML4−ALK Variant-Specific Genetic Interactions Shape Lung Tumorigenesis
Supplementary Table 7 shows the prevalence of alterations in all genes assayed for the five most commonly occurring EML4-ALK variants in the NSCLC cohort (V3, V1, V2, V5' and V5).
- Open Access
- 12 January 2026
- Published by American Association for Cancer Research (AACR)
Figure S8 from EML4−ALK Variant-Specific Genetic Interactions Shape Lung Tumorigenesis
Supplementary Figure 8 shows histological analysis and quantification of cancer type marker gene expression and signaling protein phosphorylation in EML4-ALK V1 and V3 tumors of different tumor suppressor genotypes
- 12 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S8 from EML4−ALK Variant-Specific Genetic Interactions Shape Lung Tumorigenesis
Supplementary Figure 8 shows histological analysis and quantification of cancer type marker gene expression and signaling protein phosphorylation in EML4-ALK V1 and V3 tumors of different tumor suppressor genotypes
- Open Access
- 12 January 2026
- Published by American Association for Cancer Research (AACR)
Figure S4 from EML4−ALK Variant-Specific Genetic Interactions Shape Lung Tumorigenesis
Supplementary Figure 4 shows data on the adaptively sample mean size of tumors with each tumor suppressor gene inactivation at the sgRNA-level in the Lenti-sgTSG19-sgV1/Cre and Lenti-sgTSG19-sgV3/Cre pools in both Cas9EGFP and Cas9-negative control mice.
- 12 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from EML4−ALK Variant-Specific Genetic Interactions Shape Lung Tumorigenesis
Supplementary Figure 4 shows data on the adaptively sample mean size of tumors with each tumor suppressor gene inactivation at the sgRNA-level in the Lenti-sgTSG19-sgV1/Cre and Lenti-sgTSG19-sgV3/Cre pools in both Cas9EGFP and Cas9-negative control mice.
- Open Access
- 12 January 2026
- Published by American Association for Cancer Research (AACR)
Figure S5 from EML4−ALK Variant-Specific Genetic Interactions Shape Lung Tumorigenesis
Supplementary Figure 5 shows the schematic of Lenti-sgTSG75-sgV1/Cre and Lenti-sgTSG75-sgV3/Cre pools, tumor initiation in Cas9-negative mice to determine the representation of Lenti-sgRNA/Cre vectors, and additional data from broader screen of tumor suppressor function in V1- and V3-driven lung cancer including tumor burden, tumor number and effect.
- 12 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S5 from EML4−ALK Variant-Specific Genetic Interactions Shape Lung Tumorigenesis
Supplementary Figure 5 shows the schematic of Lenti-sgTSG75-sgV1/Cre and Lenti-sgTSG75-sgV3/Cre pools, tumor initiation in Cas9-negative mice to determine the representation of Lenti-sgRNA/Cre vectors, and additional data from broader screen of tumor suppressor function in V1- and V3-driven lung cancer including tumor burden, tumor number and effect.
- Open Access
- 12 January 2026
- Published by American Association for Cancer Research (AACR)
Table S11 from EML4−ALK Variant-Specific Genetic Interactions Shape Lung Tumorigenesis
Supplementary Table 11 shows the impact of genes (Score RTN and significance) on EML4-ALK-V3 tumorigenesis in the context of lorlatinib treatment.
- 12 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S11 from EML4−ALK Variant-Specific Genetic Interactions Shape Lung Tumorigenesis
Supplementary Table 11 shows the impact of genes (Score RTN and significance) on EML4-ALK-V3 tumorigenesis in the context of lorlatinib treatment.
- Open Access
- 12 January 2026
- Published by American Association for Cancer Research (AACR)
Figure S6 from EML4−ALK Variant-Specific Genetic Interactions Shape Lung Tumorigenesis
Supplementary Figure 6 show data on the adaptively sample mean size of tumors with each tumor suppressor gene inactivation at the sgRNA-level in the Lenti-sgTSG75-sgV1/Cre and Lenti-sgTSG75-sgV3/Cre pools in both Cas9EGFP and Cas9-negative control mice.
- 12 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S6 from EML4−ALK Variant-Specific Genetic Interactions Shape Lung Tumorigenesis
Supplementary Figure 6 show data on the adaptively sample mean size of tumors with each tumor suppressor gene inactivation at the sgRNA-level in the Lenti-sgTSG75-sgV1/Cre and Lenti-sgTSG75-sgV3/Cre pools in both Cas9EGFP and Cas9-negative control mice.
- Open Access
- 12 January 2026
- Published by American Association for Cancer Research (AACR)
Figure S2 from EML4−ALK Variant-Specific Genetic Interactions Shape Lung Tumorigenesis
Supplementary Figure 2 show the increase tumorigenesis of V3 tumors in a different mouse model, the general cloning strategy to generate the triple sgRNA vectors, and the efficiency of GFP inactivation in EML4-Alk-driven autochthonous tumors.
- 12 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from EML4−ALK Variant-Specific Genetic Interactions Shape Lung Tumorigenesis
Supplementary Figure 2 show the increase tumorigenesis of V3 tumors in a different mouse model, the general cloning strategy to generate the triple sgRNA vectors, and the efficiency of GFP inactivation in EML4-Alk-driven autochthonous tumors.
- Open Access
- 12 January 2026
- Published by American Association for Cancer Research (AACR)
Table S4 from EML4−ALK Variant-Specific Genetic Interactions Shape Lung Tumorigenesis
Supplementary Table 4 shows adaptively sampled mean (ASM) and adaptively sampled 95th percentile size (AS95) and significance of genes in the Lenti-sgTSG75 pools on EML4-ALK-V1 and V3-driven lung tumorigenesis.
- 12 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S4 from EML4−ALK Variant-Specific Genetic Interactions Shape Lung Tumorigenesis
Supplementary Table 4 shows adaptively sampled mean (ASM) and adaptively sampled 95th percentile size (AS95) and significance of genes in the Lenti-sgTSG75 pools on EML4-ALK-V1 and V3-driven lung tumorigenesis.
- Open Access
- 12 January 2026
- Published by American Association for Cancer Research (AACR)
Table S5 from EML4−ALK Variant-Specific Genetic Interactions Shape Lung Tumorigenesis
Supplementary Table 5 shows the information of the sgRNAs included in the Tuba-seqUltra pool using in the in vivo lorlatinib response experiment and their overlap with sgRNAs in the Lenti-sgTSG19 and Lenti-sgTSG75 pools.
- 12 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S5 from EML4−ALK Variant-Specific Genetic Interactions Shape Lung Tumorigenesis
Supplementary Table 5 shows the information of the sgRNAs included in the Tuba-seqUltra pool using in the in vivo lorlatinib response experiment and their overlap with sgRNAs in the Lenti-sgTSG19 and Lenti-sgTSG75 pools.
- Open Access
- 12 January 2026
- Published by American Association for Cancer Research (AACR)
Table S3 from EML4−ALK Variant-Specific Genetic Interactions Shape Lung Tumorigenesis
Supplementary Table 3 shows the information of the sgRNA vectors in the Lenti-sgTSG19-sgV1/Cre, Lenti-sgTSG19-sgV3/Cre, Lenti-sgTSG75-sgV1/Cre, Lenti-sgTSG75-sgV3/Cre pools. Each gene was targeted by two to four sgRNAs. sgRNA sequence, source and sgID are indicated.
- 12 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S3 from EML4−ALK Variant-Specific Genetic Interactions Shape Lung Tumorigenesis
Supplementary Table 3 shows the information of the sgRNA vectors in the Lenti-sgTSG19-sgV1/Cre, Lenti-sgTSG19-sgV3/Cre, Lenti-sgTSG75-sgV1/Cre, Lenti-sgTSG75-sgV3/Cre pools. Each gene was targeted by two to four sgRNAs. sgRNA sequence, source and sgID are indicated.